Rani Competitors
| RANI Stock | USD 1.23 0.03 2.50% |
Rani Therapeutics vs Molecular Partners Correlation
Good diversification
The correlation between Rani Therapeutics Holdings and MOLN is -0.17 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Rani Therapeutics Holdings and MOLN in the same portfolio, assuming nothing else is changed.
Moving together with Rani Stock
Moving against Rani Stock
| 0.78 | KOD | Kodiak Sciences | PairCorr |
| 0.7 | VRTX | Vertex Pharmaceuticals Earnings Call Tomorrow | PairCorr |
| 0.69 | VYNE | Vyne Therapeutics | PairCorr |
| 0.65 | FBIO | Fortress Biotech | PairCorr |
| 0.59 | KPTI | Karyopharm Therapeutics | PairCorr |
Rani Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Rani Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Rani and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Rani Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Rani Stock performing well and Rani Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Rani Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IPHA | 2.36 | (0.14) | 0.00 | (0.44) | 0.00 | 3.41 | 39.49 | |||
| MIST | 3.14 | 0.15 | 0.03 | 0.21 | 4.18 | 6.15 | 34.31 | |||
| CRDF | 3.88 | (0.36) | 0.00 | (0.10) | 0.00 | 9.28 | 45.59 | |||
| CYBN | 3.28 | 0.22 | 0.05 | (3.59) | 3.62 | 6.06 | 18.15 | |||
| CRBP | 3.00 | (0.97) | 0.00 | 4.84 | 0.00 | 4.60 | 26.74 | |||
| APLT | 7.14 | (2.81) | 0.00 | (0.66) | 0.00 | 10.00 | 83.66 | |||
| SGMO | 4.33 | 0.04 | 0.02 | 0.06 | 4.40 | 8.51 | 35.78 | |||
| ELTX | 2.62 | (0.29) | 0.00 | (0.16) | 0.00 | 5.63 | 21.98 | |||
| MOLN | 2.90 | 0.37 | 0.09 | (6.82) | 3.30 | 7.46 | 26.47 |
Cross Equities Net Income Analysis
Compare Rani Therapeutics and related stocks such as Innate Pharma, Milestone Pharmaceuticals, and Cardiff Oncology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| CRDF | (5.4 M) | (2.2 M) | (11.6 M) | (11.8 M) | (14.3 M) | (27.5 M) | (39.2 M) | (24.9 M) | (16.5 M) | (16.4 M) | (19.3 M) | (28.3 M) | (38.7 M) | (41.4 M) | (45.4 M) | (40.9 M) | (38.8 M) |
| CRBP | (887) | (887) | (887) | (602.4 K) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (55.8 M) | (44.6 M) | (40.2 M) | (36.2 M) | (38 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| SGMO | (308 K) | (35.8 M) | (22.3 M) | (26.6 M) | (26.4 M) | (40.7 M) | (71.7 M) | (54.6 M) | (68.3 M) | (75.8 M) | (121.1 M) | (178.3 M) | (192.3 M) | (257.8 M) | (97.9 M) | (88.1 M) | (83.7 M) |
| ELTX | 307.3 K | 307.3 K | 307.3 K | 632.2 K | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (40.7 M) | (80.1 M) | (26.4 M) | (28.2 M) | (35.2 M) | (51.9 M) | (46.7 M) | (49 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
Rani Therapeutics and related stocks such as Innate Pharma, Milestone Pharmaceuticals, and Cardiff Oncology Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Rani Therapeutics financial statement analysis. It represents the amount of money remaining after all of Rani Therapeutics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Rani Therapeutics Competitive Analysis
The better you understand Rani Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Rani Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Rani Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Rani Therapeutics Competition Performance Charts
Five steps to successful analysis of Rani Therapeutics Competition
Rani Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Rani Therapeutics in relation to its competition. Rani Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Rani Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Rani Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Rani Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Rani Therapeutics position
In addition to having Rani Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities Thematic Idea Now
Utilities
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Rani Therapeutics Correlation with its peers. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value—what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.